ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
BlinFant: A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
Protocol ID
NL59901.078.17 (BlinFant)
Disease (Sub Disease)
Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage
New diagnosis
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Princess Maxima Center for Pediatric Oncology & Utrecht
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Pilot
Age Eligibility
<12 months
ANZCTR
ACTRN12620000542998
Back to Registry
Study Title BlinFant: A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
Protocol ID NL59901.078.17 (BlinFant)
Disease (Sub Disease) Acute Lymphoblastic Leukaemia (ALL)
Diagnosis Stage New diagnosis
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ Princess Maxima Center for Pediatric Oncology & Utrecht
Links https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379482&isReview=true
Trial Status Closed to Recruitment
Trial Open Date 20/07/2018
Study Type Treatment
Phase Pilot
Age Eligibility <12 months
ANZCTR ACTRN12620000542998

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168